NYSE$IBIO
iBio Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
iBio's Q4 2021 financial results and corporate update were announced, highlighting the expansion of the immuno-oncology pipeline, advancements in the COVID-19 vaccine candidate, and growth in the bioprocess segment.
iBio reported a revenue of $0.5 million for the fourth quarter ended June 30, 2021, a decrease of $0.6 million from Q4 FY2020, and a consolidated net gain of $0.1 million due to Settlement Income.
- iBio established a new oncology drug discovery team in San Diego.
- The company signed a definitive worldwide exclusive license agreement with RubrYc Therapeutics, Inc.
- iBio submitted a pre-IND package for IBIO-202.
- Revenues in the services business were up 50% over prior year.
Headline financials
Revenue & EPS history
iBio · Revenue · Quarterly
$491K
Forward guidance
iBio anticipates a sequential decline in revenue during the first half of fiscal 2022 compared to the second half of fiscal 2021, followed by higher growth in the second half of fiscal 2022.
Tailwinds
- Continued year-on-year revenue growth is anticipated as the Bioprocess businesses continue to attract interest.
- iBio expects higher growth in the second half of fiscal 2022.
- The company invested in additional staff and made external investments to implement its strategy.
- The current cash position is sufficient to fund operations through the first calendar quarter of 2023.
- iBio expects R&D and G&A will continue to grow in fiscal 2022.
Headwinds
- iBio expects a sequential decline in revenue during the first half of fiscal 2022 compared to the second half of fiscal 2021.
- Significant quarter-to-quarter revenue variability is commonplace for early-stage pharma services companies.
- R&D and G&A expenses for the fourth quarter and full fiscal year 2021 increased significantly over the comparable periods in fiscal year 2020.
- iBio used $30.1 million in net cash for operating activities in fiscal 2021 versus net cash used in operating activities of $13.3 million in 2020.
- iBio anticipates a slower growth rate of R&D and G&A in fiscal 2022 compared to fiscal 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-1.4%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+14.3%
Avg return
30 days after
43%
17 / 40 earnings
Positive
+24.4%
Q3 2020
Best reaction
-34.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +12.9% | +9.9% | +22.8% | |
| Q1 2026 | -8.0% | -3.2% | +55.2% | |
| Q4 2025 | +3.7% | +8.6% | +6.2% | |
| Q3 2025 | +1.3% | +1.3% | +30.4% | |
| Q2 2025 | -14.8% | -7.8% | +49.2% | |
| Q1 2025 | -9.4% | -10.9% | -2.0% | |
| Q4 2024 | -2.6% | -4.2% | +51.1% | |
| Q3 2026 | -3.7% | +23.9% | +36.2% | |
| Q3 2024 | +1.6% | +7.0% | +37.8% | |
| Q2 2024 | +5.2% | +5.2% | +2.6% | |
| Q1 2024 | -3.4% | -10.3% | -78.1% | |
| Q4 2023 | -3.3% | -9.1% | -6.1% | |
| Q3 2023 | -7.9% | -5.9% | -31.7% | |
| Q2 2023 | -10.5% | +55.8% | +113.7% | |
| Q1 2023 | +0.0% | -8.6% | -68.6% | |
| Q4 2022 | -34.4% | -46.9% | -74.6% | |
| Q3 2022 | +0.0% | +0.0% | +12.0% | |
| Q2 2022 | +2.7% | -8.1% | -5.4% | |
| Q1 2022 | -9.2% | -11.8% | -17.1% | |
| Q4 2021 | -4.3% | -11.1% | -35.0% | |
| Q3 2021 | -6.8% | -0.7% | +5.4% | |
| Q2 2021 | -15.3% | -17.8% | -29.8% | |
| Q1 2021 | +15.2% | -9.6% | -38.2% | |
| Q3 2020 | +24.4% | +16.0% | +31.9% | |
| Q2 2020 | -10.5% | -21.1% | +321.1% | |
| Q1 2020 | +13.3% | -26.7% | +46.7% | |
| Q3 2019 | +7.3% | -2.4% | -4.9% | |
| Q2 2019 | -2.2% | -4.4% | -6.7% | |
| Q1 2019 | +4.0% | +9.3% | -10.7% | |
| Q1 2015 | +3.4% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q1 2013 | -1.9% | — | — | |
| Q3 2012 | -9.8% | — | — | |
| Q1 2010 | +1.8% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q4 2011 | -3.0% | — | — | |
| Q3 2011 | +4.8% | — | — | |
| Q2 2010 | +3.4% | — | — | |
| Q4 2010 | +1.4% | — | — | |
| Q3 2010 | -1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro